A Prospective, Randomized, Placebo-controlled, Multicenter, International Phase I/II Trial of RAD001 (Everolimus) in Combination With DHAP as Induction Therapy in Patients With Relapsed or Refractory Hodgkin Lymphoma (HL)
Phase of Trial: Phase I/II
Latest Information Update: 18 May 2017
At a glance
- Drugs Everolimus (Primary) ; Cisplatin; Cytarabine; Dexamethasone
- Indications Hodgkin's disease
- Focus Adverse reactions; Therapeutic Use
- 10 May 2017 Planned primary completion date changed from 1 Aug 2016 to 1 Aug 2017.
- 14 Jul 2014 Planned End Date changed from 1 Aug 2016 to 1 Aug 2018 as reported by ClinicalTrials.gov record.
- 25 Sep 2012 Planned End Date changed from 1 Jul 2016 to 1 Aug 2016 as reported by ClinicalTrials.gov.